Kineta to Present at the Oppenheimer 33rd Annual Healthcare
SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-03-08, 18:34
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-03-06, 18:39
Kineta to Host Key Opinion Leader Event on KVA12123: VISTA
SEATTLE, March 06, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on developing next-generation...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-03-01, 18:52
Kineta Appoints Internationally-Renowned Clinical
SEATTLE, March 01, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on developing next-generation...
